Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Pembrolizumab, emavusterib + radiosurgery: a novel trimodal therapy for metastatic melanoma

Bently Doonan • 14 Jun 2022
ASCO 2022
Melanoma Skin Cancer Antibodies Checkpoint Inhibitors Pembrolizumab

Bently Doonan, MD, University of Florida, Gainesville, FL, talks on a up and coming clinical trial involving a novel trimodal therapy of pembrolizumab and emavusertib (CA-4948) with radiosurgery to optimize treatment for metastatic melanoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Bently Doonan

2:26
Overcoming barriers in treating melanoma brain metastases
Bently Doonan • 7 Jun 2022
3:51
Evaluating the mechanism of action of emavusertib
Bently Doonan • 7 Jun 2022
1:22
Advancing cancer therapeutics for brain metastases
Bently Doonan • 14 Jun 2022

Related Videos

2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
1:20
Can ctDNA guide the treatment decision making process in melanoma?
Christoffer Gebhardt • 9 Apr 2024
1:18
Elucidating ICI resistance in melanoma with ctDNA and tumor profiling
Christoffer Gebhardt • 9 Apr 2024
1:48
Ultra-sensitive ctDNA monitoring predicts ICI response in melanoma
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals